Company logo

BCRX - BioCryst Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
Durham, United States

BCRX price evolution
BCRX
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $203.89 $214.66 $230.91 $274.35
Short term investments $8.11 $13.45 $28.24
Net receivables $26.21 $27.62 $18.39 $8.65
Inventory $13.66 $9.85 $5.11 $7.04
Total current assets $252.74 $265.8 $273.77 $323.8
Long term investments
Property, plant & equipment $7.83 $7.67 $7.04 $7.11
Goodwill & intangible assets
Total noncurrent assets $13.02 $11.48 $10.66 $10.91
Total investments $8.11 $13.45 $28.24
Total assets $265.76 $277.28 $284.43 $334.71
Current liabilities
Accounts payable $19.69 $10.09 $13.53 $18.71
Deferred revenue $0.6 $0.55 $0.41 $0.15
Short long term debt $31.45 $30.98 $31 $31.18
Total current liabilities $133.61 $115.6 $101.2 $105.65
Long term debt $279.2 $267.76 $258.22 $248.32
Total noncurrent liabilities $279.2 $267.76 $258.22 $248.32
Total debt $310.65 $298.74 $289.22 $279.5
Total liabilities $412.81 $383.36 $359.42 $353.98
Shareholders' equity
Retained earnings -$1189.72 -$1130.92 -$1087.73 -$1023.44
Other shareholder equity $0.11 $0.09 $0.18 $0
Total shareholder equity -$147.04 -$106.08 -$74.99 -$19.26
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $274.35 $115.72 $28.27 $53.57
Short term investments $28.24 $22.05 $77.74 $64.11
Net receivables $8.65 $22.15 $4.29 $6.12
Inventory $7.04 $1.65
Total current assets $323.8 $164.34 $114.35 $125.39
Long term investments $22.38 $41.3
Property, plant & equipment $7.11 $7.35 $9.13 $9.55
Goodwill & intangible assets
Total noncurrent assets $10.91 $10.94 $32.49 $52.87
Total investments $28.24 $22.05 $100.11 $105.41
Total assets $334.71 $175.28 $146.84 $178.26
Current liabilities
Accounts payable $18.71 $13.99 $7.77 $6.34
Deferred revenue $0.15 $2.12 $0.22 $8.48
Short long term debt $31.18 $39.96 $33.75 $35.22
Total current liabilities $105.65 $92.33 $69.48 $74.84
Long term debt $248.32 $44.7 $28.07 $19.5
Total noncurrent liabilities $248.32 $44.7 $28.13 $19.66
Total debt $279.5 $84.65 $61.82 $54.72
Total liabilities $353.98 $137.03 $97.61 $94.49
Shareholders' equity
Retained earnings -$1023.44 -$840.63 -$731.97 -$631.84
Other shareholder equity $0 $0.04 -$0.3 -$0.24
Total shareholder equity -$19.26 $38.25 $49.23 $83.77
(in millions $) 30 Sep 2021 30 Jul 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $40.99 $49.96 $19.06 $4.02
Cost of revenue $0.61 $0.34 $5.89 $0.08
Gross Profit $40.38 $49.62 $13.17 $3.94
Operating activities
Research & development $49.97 $52.87 $42.44 $35.35
Selling, general & administrative $34.99 $26.32 $22.11 $20.99
Total operating expenses $84.96 $79.2 $64.55 $56.34
Operating income -$44.58 -$29.58 -$51.38 -$52.41
Income from continuing operations
EBIT -$44.7 -$29.7 -$51.38 -$54.88
Income tax expense
Interest expense $14.11 $13.49 $12.9 $5.61
Net income
Net income -$58.8 -$43.2 -$64.28 -$60.49
Income (for common shares) -$58.8 -$43.2 -$64.28 -$60.49
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue $17.81 $48.84 $20.65 $25.19
Cost of revenue $1.68 $4.1 $0.47 $1.7
Gross Profit $16.14 $44.73 $20.18 $23.48
Operating activities
Research & development $122.96 $107.07 $84.89 $66.96
Selling, general & administrative $67.93 $37.12 $29.51 $13.93
Total operating expenses $190.89 $144.19 $114.4 $80.89
Operating income -$174.76 -$99.45 -$94.22 -$57.41
Income from continuing operations
EBIT -$168.31 -$97 -$92.08 -$57.22
Income tax expense
Interest expense $14.5 $11.89 $9.18 $8.56
Net income
Net income -$182.81 -$108.9 -$101.25 -$65.78
Income (for common shares) -$182.81 -$108.9 -$101.25 -$65.78
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income -$58.8 -$43.2 -$64.28 -$60.49
Operating activities
Depreciation $0.23 $0.2 $0.18 $0.18
Business acquisitions & disposals
Stock-based compensation $13.03 $7.63 $5.48 $5.89
Total cash flows from operations -$23.28 -$25.41 -$61.01 -$44.64
Investing activities
Capital expenditures -$0.36 -$0.81 -$0.1 -$0.15
Investments $8.11 $5.32 $14.77 $21.57
Total cash flows from investing $7.75 $4.5 $14.67 $21.41
Financing activities
Dividends paid
Sale and purchase of stock $4.78 $4.57 $2.9 $1.71
Net borrowings $197.16
Total cash flows from financing $4.78 $4.57 $2.9 $198.87
Effect of exchange rate -$0.02 $0.09
Change in cash and equivalents -$10.77 -$16.25 -$43.44 $175.64
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income -$182.81 -$108.9 -$101.25 -$65.78
Operating activities
Depreciation $0.75 $0.72 $0.77 $0.7
Business acquisitions & disposals
Stock-based compensation $14.79 $17.72 $9.4 $12.62
Total cash flows from operations -$137.22 -$89.58 -$92.56 -$41.14
Investing activities
Capital expenditures -$0.51 -$0.34 -$0.37 -$0.32
Investments -$6.34 $78.28 $5.13 -$64.33
Total cash flows from investing -$6.86 $77.93 $4.77 -$66.38
Financing activities
Dividends paid
Sale and purchase of stock $95.72 $59.74 $56.25 $135.58
Net borrowings $192.16 $19.48 $6.25 $0.12
Total cash flows from financing $302.7 $99.1 $62.5 $135.7
Effect of exchange rate
Change in cash and equivalents $158.63 $87.45 -$25.29 $28.18
Fundamentals
Market cap $2.64B
Enterprise value $2.74B
Shares outstanding 179.94M
Revenue $114.03M
EBITDA -$179.88M
EBIT -$180.66M
Net Income -$226.78M
Revenue Q/Q 571.81%
Revenue Y/Y 113.05%
P/E ratio -11.62
EV/Sales 24.05
EV/EBITDA -15.25
EV/EBIT -15.18
P/S ratio 23.12
P/B ratio -17.91
Book/Share -0.82
Cash/Share 1.13
EPS -$1.26
ROA -78.05%
ROE 261.14%
Debt/Equity -18.38
Net debt/EBITDA -1.16
Current ratio 1.89
Quick ratio 1.79